Drug Profile


Alternative Names: PRO-040201; TKM-ApoB

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Tekmira Pharmaceuticals Corporation
  • Developer Arbutus Biopharma
  • Class Antihyperlipidaemics; Small interfering RNA
  • Mechanism of Action Apolipoprotein B inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hypercholesterolaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hypercholesterolaemia in USA (Parenteral)
  • 11 Jan 2010 Tekmira completes a phase I trial in Hypocholesterolaemia in the US
  • 02 Jul 2009 Phase-I clinical trials in Hypercholesterolaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top